United Therapeutics Corp (UTHR)
363.63
-22.64
(-5.86%)
USD |
NASDAQ |
Nov 15, 11:35
United Therapeutics Research and Development Expense (Quarterly): 103.50M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 103.50M |
| June 30, 2024 | 139.60M |
| March 31, 2024 | 104.10M |
| December 31, 2023 | 151.40M |
| September 30, 2023 | 84.70M |
| June 30, 2023 | 89.00M |
| March 31, 2023 | 82.90M |
| December 31, 2022 | 93.90M |
| September 30, 2022 | 66.10M |
| June 30, 2022 | 93.90M |
| March 31, 2022 | 69.00M |
| December 31, 2021 | 82.90M |
| September 30, 2021 | 79.20M |
| June 30, 2021 | 74.30M |
| March 31, 2021 | 303.70M |
| December 31, 2020 | 126.10M |
| September 30, 2020 | 68.70M |
| June 30, 2020 | 89.70M |
| March 31, 2020 | 73.20M |
| December 31, 2019 | 113.60M |
| September 30, 2019 | 85.70M |
| June 30, 2019 | 85.90M |
| March 31, 2019 | 897.40M |
| December 31, 2018 | 138.80M |
| September 30, 2018 | 101.10M |
| Date | Value |
|---|---|
| June 30, 2018 | 82.30M |
| March 31, 2018 | 35.70M |
| December 31, 2017 | 113.60M |
| September 30, 2017 | 55.00M |
| June 30, 2017 | 59.80M |
| March 31, 2017 | 36.20M |
| December 31, 2016 | 66.90M |
| September 30, 2016 | 45.90M |
| June 30, 2016 | 35.20M |
| March 31, 2016 | -0.40M |
| December 31, 2015 | 75.90M |
| September 30, 2015 | 9.60M |
| June 30, 2015 | 49.40M |
| March 31, 2015 | 110.20M |
| December 31, 2014 | 71.43M |
| September 30, 2014 | 118.88M |
| June 30, 2014 | 39.74M |
| March 31, 2014 | 12.45M |
| December 31, 2013 | 121.55M |
| September 30, 2013 | 72.75M |
| June 30, 2013 | 54.62M |
| March 31, 2013 | 50.43M |
| December 31, 2012 | 37.48M |
| September 30, 2012 | 65.16M |
| June 30, 2012 | 37.10M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
66.10M
Minimum
Sep 2022
303.70M
Maximum
Mar 2021
104.48M
Average
89.35M
Median
Research and Development Expense (Quarterly) Benchmarks
| Liquidia Corp | 9.42M |
| Pfizer Inc | 2.598B |
| Tonix Pharmaceuticals Holding Corp | 9.698M |
| Ardelyx Inc | 15.31M |
| Cingulate Inc | 1.428M |